

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Evaluation of Intravitreal injection of Bevacizumab for treatment of Chronic Central Serous Chorioretinopathy

Protocol summary

Summary

Aim: Evaluation of intravitreal injection of Bevacizumab for treatment of chronic central serous chorioretinopathy . Design:Prospective, Consecutive , non randomized Clinical Trial. Participants and Intervention: 15 patient of Acute Central Serous Chorioretinopathy That is not Anatomically improved for more than 4-months(Persistent Macular Sub-Sensory Retinal Fluid)will receive 0.1 cc/2.5 mg of Avastin Intravitreally .Before Injection ,The diagnosis should be Confirmed by Ocular Coherent Tomography(OCT) and Fluorescein Angiography (FFA) .Also all the Patients will be examined by another ophthalmologist (Supervisor of The Study)and The diagnosis of the Chronic Central Serous Chorioretinopathy should be Confirmed by him.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201202198983N1**
Registration date: **2012-03-17, 1390/12/27**
Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2012-03-17, 1390/12/27

Registrant information

Name

Mohammad rasoul Sabouri

Name of organization / entity

Guilan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 13 1223 6886

Email address

sabouri@gums.ac.ir

Recruitment status

Recruitment complete

Funding source

Guilan university of medical sciences

Expected recruitment start date

2012-02-19, 1390/11/30

Expected recruitment end date

2014-02-19, 1392/11/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of Intravitreal injection of Bevacizumab for treatment of Chronic Central Serous Chorioretinopathy

Public title

Evaluation of Intravitreal injection of Bevacizumab for treatment of Chronic Central Serous Chorioretinopathy

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria : 1- patient by Acute Central Serous Chorioretinopathy for more than 4-months. 2- Confirmation of The Chronic Central Serous Chorioretinopathy by Ocular Coherent Tomography(OCT) and Fluorescein Angiography (FFA) . 3- confirmation of the Disease by Supervisor of Study. Exclusion criteria: 1- Chronic Central Serous Chorioretinopathy more than 2 years. 2- History of Treatment by any type of Laser. 3- History of Thromboembolic Disease Like Myocardial Infarction and Cerebro Vascular accident. 4- History of Treatment by Intravitreal Avastin during 2 months ago. 5- any systemic Disease that need Oral Corticosteroid Therapy. 6- un - Controlled Glaucoma 7- Pregnancy 8- Lack

of agreement by Patient for periodic Follow up during study.

Age

From **20 years** old to **50 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **15**

Randomization (investigator's opinion)

N/A

Randomization description**Blinding (investigator's opinion)**

Not blinded

Blinding description**Placebo**

Not used

Assignment

Single

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Guilan University of Medical Sciences

Street address

Amiralmomenin Hospital, 17 Shahrivar Ave, Rasht, Guilan, Iran

City

Rasht

Postal code

4139637459

Approval date

2012-01-11, 1390/10/21

Ethics committee reference number

1901130501

Health conditions studied**1****Description of health condition studied**

chronic central serous chorioretinopathy

ICD-10 code

VII

ICD-10 code description

Disease of the eye and adnexa

Primary outcomes**1****Description**

Vision Improvement

Timepoint

every 6 to 8 weeks until 6 month

Method of measurement

Snellen Chart

2**Description**

Anatomical Improvement

Timepoint

every 6 to 8 weeks until 6 month

Method of measurement

Clinical exam and OCT

Secondary outcomes**1****Description**

central thickness of retin

Timepoint

per 6-8 weeks till 6 month

Method of measurement

with OCT.If in the first examination(by OCT) after weeks 6 to 8 ,at least 10 % reduction in the central macular thickness occur,the patient will be periodically follow,if not ,the patient will be omitted.

Intervention groups**1****Description**

In the operating room, under local anesthesia, and MAC and sterile condition by using 10% & 5% Betadine for periorbital and culdesac area and prep & drape and insertion of speculum and after 0.1 cc AC-tap ,0.1cc/2.5 mg Bevacizumab(Avastin) will be injected through superior / inferior temporal quadran 3.5 mm away from limbus using 30- guage needle

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Amiralmomenin Hospital

Full name of responsible person

dr mohammad rasoul sabouri

Street address

17 shahrivar street

City

Rasht

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Guilan University of Medical Sciences, Pro-vice-chancellor for research

Full name of responsible person

Susan Komaie

Street address

Pro-vice Chancellor for Research, Namjoo Ave, Mellat St, Rasht, Guilan, Iran

City

Rasht

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Guilan University of Medical Sciences, Pro-vice-chancellor for research

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries

Contact**Name of organization / entity**

Guilan University of Medical Sciences

Full name of responsible person

Dr Mohammad Rasoul Sabouri

Position

Assistant Professor

Other areas of specialty/work**Street address**

Amiralmomenin Hospital, 17 Shahrivar Ave, Rasht, Guilan, Iran

City

Rasht

Postal code**Phone**

+98 13 1223 6886

Fax**Email**

sabouri@gums.ac.ir

Web page address

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Guilan University of Medical Sciences

Full name of responsible person

Dr Mohammad Rasoul Sabouri

Position

Assistant professor

Other areas of specialty/work**Street address**

Amiralmomenin Hospital, 17 Shahrivar Ave, Rasht, Guilan, Iran

City

Rasht

Postal code**Phone**

+98 13 1223 6886

Fax**Email**

sabouri@gums.ac.ir

Web page address

Person responsible for updating data

Contact**Name of organization / entity**

Guilan University of Medical Sciences

Full name of responsible person

Dr Mohammad Rasoul Sabouri

Position

Assistant Professor

Other areas of specialty/work**Street address**

Amiralmomenin Hospital, 17 Shahrivar Ave, Rasht, Guilan, Iran

City

Rasht

Postal code

0098

Phone

+98 13 1223 6886

Fax

+98 13 1223 6886

Email

sabouri@gums.ac.ir

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty